THE PRICE of medicine can mean the difference between recovery and prolonged suffering, and illness can push struggling families deeper into poverty. Yet, a dangerous misconception persists among households: that expensive branded medicines are necessarily safer and more effective than cheaper generic alternatives. This belief is not merely misguided. For families already struggling to survive, it can be financially devastating.
The Department of Health (DOH) in Western Visayas is confronting this misconception at the grassroots. By mobilizing barangay health workers (BHWs) to educate communities about generic medicines, the agency is challenging a deeply ingrained perception that equates price with quality.
During the recent Generics Awareness Month celebration in San Miguel, Iloilo, health authorities emphasized that FDA-approved generic medicines contain the same active ingredients as their branded equivalents and must meet regulatory standards for safety, quality and effectiveness. Their lower prices do not make them inferior.
Unfortunately, misinformation continues to discourage patients from choosing affordable treatment. When financially struggling families insist on expensive branded medicines despite the availability of appropriate generic alternatives, money intended for food, education and other necessities is unnecessarily sacrificed. Worse, patients unable to afford costly prescriptions may delay treatment, reduce dosages or abandon medication altogether.
This is where barangay health workers become indispensable. These community frontliners understand the realities of poverty. They encounter elderly residents struggling to afford maintenance medicines, parents choosing between prescriptions and household expenses, and patients whose illnesses worsen because treatment is financially beyond their reach.
But education alone is insufficient. The government must also confront pharmaceutical marketing practices that reinforce the perception that expensive brands are inherently superior. Healthcare professionals must prioritize medical appropriateness, proven effectiveness and affordability over brand prestige.
Equally important, affordable generic medicines must be consistently available in public health facilities and pharmacies. What good is convincing patients to choose cheaper alternatives if these medicines are unavailable when needed? Public confidence requires reliable supplies, strict quality monitoring and effective regulation.
The DOH must also provide barangay health workers with sustained training and adequate institutional support. Their expanding responsibilities should never become an excuse for government to underinvest in grassroots healthcare.
Ultimately, the campaign against generic medicine misinformation is a campaign against healthcare inequality. Wealthier patients can absorb expensive prescriptions. Poor families cannot. For them, every unnecessary peso spent on medicine represents another sacrifice in an already strained household budget.
Generic medicine education must therefore become a permanent public health priority, not merely a ceremonial activity confined to September. Patients deserve to understand that the value of medicine lies in its proven quality, effectiveness and suitability for treatment — not its brand name or price tag.
The real scandal is not that generic medicines are cheap. It is that misinformation continues to make poor Filipinos pay more than necessary for healthcare they desperately need.
